MUMBAI (Reuters) - India's largest drugmaker Sun Pharmaceutical Industries Ltd's third-quarter profit fell below analysts' estimates due to slower sales in the United States, its largest market.
Sun's net profit for the October-December period fell to 14.72 billion rupees ($219.87 million) from 15.45 billion rupees a year earlier. Analysts on average expected a profit of 17.83 billion rupees, according to Thomson Reuters I/B/E/S.
Sun said quarterly U.S. sales rose 4 percent over the year earlier. The company's U.S. subsidiary Taro Pharmaceutical Industries Ltd last week reported third-quarter sales down 15 percent over the last year.
($1 = 66.9500 rupees)
(Reporting by Zeba Siddiqui in Mumbai; Editing by Himani Sarkar and Vyas Mohan)
Disclaimer: No Business Standard Journalist was involved in creation of this content
